Cypherpunk Technologies (NASDAQ:CYPH) Director Thomas John Dietz Sells 20,000 Shares

Cypherpunk Technologies (NASDAQ:CYPH) Director Thomas John Dietz sold 20,000 shares of the company’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $1.72, for a total transaction of $34,400.00. Following the completion of the transaction, the director owned 132,500 shares of the company’s stock, valued at $227,900. This trade represents a 13.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Cypherpunk Technologies Price Performance

Shares of CYPH stock opened at $1.89 on Friday. Cypherpunk Technologies has a 12 month low of $0.27 and a 12 month high of $3.70. The firm has a market capitalization of $203.67 million, a P/E ratio of 3.37 and a beta of 0.09. The company’s fifty day moving average price is $0.79 and its two-hundred day moving average price is $0.82.

Cypherpunk Technologies (NASDAQ:CYPH) last posted its quarterly earnings data on Wednesday, August 12th. The company reported $0.18 earnings per share for the quarter.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Weiss Ratings upgraded Cypherpunk Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 17th. Cantor Fitzgerald reiterated an “overweight” rating and set a $1.60 target price on shares of Cypherpunk Technologies in a research note on Thursday. Finally, Wall Street Zen raised shares of Cypherpunk Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, July 4th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Cypherpunk Technologies currently has a consensus rating of “Hold” and a consensus target price of $1.60.

Hedge Funds Weigh In On Cypherpunk Technologies

Large investors have recently modified their holdings of the stock. Millennium Management LLC acquired a new position in Cypherpunk Technologies in the fourth quarter worth about $37,000. LPL Financial LLC acquired a new stake in Cypherpunk Technologies during the fourth quarter valued at approximately $38,000. Caitong International Asset Management Co. Ltd acquired a new stake in Cypherpunk Technologies during the fourth quarter valued at approximately $44,000. Sequoia Financial Advisors LLC bought a new position in Cypherpunk Technologies during the 4th quarter worth approximately $56,000. Finally, HighTower Advisors LLC bought a new position in Cypherpunk Technologies during the 4th quarter worth approximately $59,000. Institutional investors own 30.46% of the company’s stock.

About Cypherpunk Technologies

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.